New findings highlight microRNAs — molecules that regulate gene expression — that are differentially expressed in glaucoma and could be candidate biomarkers or targets for therapy.

The rates of myopia, or nearsightedness, in pediatric patients have steadily increased with little to no change in treatment, which, for decades, has had ophthalmologists and optometrists turning to corrective lenses for improved vision.

A team of researchers, led by David Calkins, PhD, vice chair and director of Research at the Vanderbilt Eye Institute, has made a breakthrough discovery in the field of glaucoma showing new hopes for treatments to preserve vision.

Paul Sternberg Jr., MD, George Weeks Hale Professor and chair of Ophthalmology and Visual Sciences at Vanderbilt, was recently named president-elect of the Association of University Professors of Ophthalmology (AUPO).

Prescription opioid abuse is at epidemic levels, and Vanderbilt University Medical Center’s Shriji Patel, M.D., assistant professor of Ophthalmology and Visual Sciences, wanted to find out what part, if any, his colleagues play in the crisis.

Vanderbilt researcher Tonia Rex, Ph.D., is accustomed to performing studies in her lab with a goal of translating the findings into better diagnoses and treatment tools for the visually impaired.

The Vanderbilt Eye Institute (VEI) recently hosted the Southeastern Vision Conference to celebrate and share excellence in vision science.